Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

被引：0
|
作者：
Song, Zhengbo [1 ]
Zhang, Yiping [2 ]
Yuz, Xinmin [1 ]
机构：
[1] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Thymidylate synthetase; ros1; pemetrexed; efficacy;
D O I：
10.1016/j.jtho.2016.11.1659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-029
引用
收藏
页码：S1179 / S1180
页数：2
相关论文
共 50 条
  • [1] Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy
    Song, Zhengbo
    Su, Haiyan
    Zhang, Yiping
    CANCER MEDICINE, 2016, 5 (10): : 2688 - 2693
  • [2] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [3] Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
    Zhang, Limin
    Jiang, Tao
    Zhao, Chao
    Li, Wei
    Li, Xuefei
    Zhao, Sha
    Liu, Xiaozhen
    Jia, Yijun
    Yang, Hui
    Ren, Shengxiang
    Zhou, Caicun
    ONCOTARGET, 2016, 7 (46) : 75145 - 75154
  • [4] Efficacy of Crizotinib and Pemetrexed-Based Chemotherapy in Chinese NSCLC Patients with ROS1 Rearrangement
    Zhang, Limin
    Jiang, Tao
    Zhao, Chao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1501 - S1501
  • [5] Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.
    Shen, Lan
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Pemetrexed-based chemotherapy in advanced nonsquamous non-small cell lung cancer (NSCLC).
    Alshehri, Abdulrahman Ali
    Alsubait, Saud Abdullrhman
    Alamgir, M. Ahsan
    Park, Chandler
    Wen, Sijin
    Luo, Jin
    Ma, Patrick
    Monga, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer
    Yang, Jungho
    Pyo, Jung-Soo
    Kang, Guhyun
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04): : 520 - 527
  • [8] Patients with EGFR exon 20 insertion mutation non-small cell lung cancer benefit from pemetrexed-based chemotherapy: A multicenter study
    Wang, W.
    Xu, C.
    Lei, L.
    Wang, D.
    Pu, X.
    Zhu, Y.
    Huang, J.
    Yu, Z.
    Li, J.
    Fang, Y.
    Wang, H.
    Zhuang, W.
    Lan, S.
    Cai, X.
    Zhang, Y.
    Gao, W.
    Wang, L.
    Fang, M.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S859 - S859
  • [9] ROS1 positive Non-Small Cell Lung Cancer clinical case
    Silva, Sonia
    Feijo, Salvato
    MEDICINE, 2020, 99 (23)
  • [10] Efficacy of pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with ROS-1 rearrangement
    Zhang, B.
    Chu, T.
    Xu, J.
    Zhang, Y.
    Yan, B.
    Dong, Y.
    Qian, J.
    Qiao, R.
    Wang, S.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S100 - S100
12345